Amarin stock jumps on patent progress for blockbuster hopeful; OncoGenex seeks $46.8M in stock sale;

 

 @FierceBiotech: Analysis on biotech VC math by via @LifeSciVC explains why smaller funds make sense. Report | Follow @FierceBiotech

 @JohnCFierce: Ian Read's comp jumped 44%, to $25 million, when he get the big promo at Pfizer. Item | Follow @JohnCFierce

 @RyanMFierce: Active Biotech up on news that partner Teva plans to seek European OK for MS drug $ACTI $TEVA. Story | Follow @RyanMFierce

@FierceMedDev: Sanofi to buy U.S. medical device company Pluromed via @Reuters. News | Follow @FierceMedDev

> Drug developer Amarin's ($AMRN) stock jumped today upon renewed confidence that it was making progress securing patent protections for AMR10, its omega-3 drug that's viewed as a potential blockbuster. Item

> Medco Health Solutions reports that its analyses show that drugs for heartburn and other ailments can hurt the efficacy and boost the toxicity of certain cancer meds. Report

> OncoGenex Pharmaceuticals ($OGXI) said today that it plans to raise $46.8 million through a stock offering, which follows the Bothell, WA-based company's announcement last week that it's expanding a trial for its lead drug for prostate cancer. OncoGenex release

> Threshold Pharmaceuticals ($THLD) has garnered orphan status from the European Commission for its experimental med TH-302, which is a hypoxia-targeted drug for treating soft tissue sarcoma. Article

Pharma News

 @FiercePharma: EMA orders production of cancer meds Caelyx (aka Doxil) and Ceplene to be moved from Ben Venue plant $JNJ $EPCT. News | Follow @FiercePharma

> Novartis persuades NICE to endorse Gilenya. Article

> Setting new course, Pfizer CEO gets 44% pay hike. Item

> Hamburg says FDA needs more leeway to combat drug fakes. News

> Can European pharma's cash flow cover buyback plans? Story

> Mylan bows out of Rottapharm bidding. Item

And Finally… Their advances spurned by their female counterparts, male fruit flies hit the proverbial bottle and eat alcohol-laden foods. Article

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.